DERL2

Across TCGA pan-cancer cohorts, DERL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DERL2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DERL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DERL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where DERL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.131	0.861	.001	21	view →
HNSC	DFS	Median	III,IV	0.748	0.457	.001	17	view →
LUAD	DFS	Quartile	II,III,IV	0.554	0.853	.043	3	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
LSCC	DFS	Median	II,III,IV	0.568	0.819	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DERL2–CCRCC (DFS)

Open the CCRCC breakdown →